• Edesa Biotech shifted CEO Pardeep Nijhawan’s compensation mix, issuing 90% of his monthly base salary as fully vested restricted share units (RSUs) under its 2019 Equity Incentive Compensation Plan, effective May 13, 2026.
• Monthly RSU awards will be set by dividing 90% of monthly base salary by fair market value of common shares at each month-end.
• Remaining 10% of monthly base salary will continue to be paid in cash.
• Change increases equity portion from prior level of 50% of base salary paid as RSUs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-003459), on May 15, 2026, and is solely responsible for the information contained therein.